KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Non Operating Income (2023 - 2025)

Historic Non Operating Income for Fulgent Genetics (FLGT) over the last 3 years, with Q3 2025 value amounting to $7.8 million.

  • Fulgent Genetics' Non Operating Income rose 63964.21% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 1216.84%. This contributed to the annual value of $22.0 million for FY2024, which is 241.56% up from last year.
  • As of Q3 2025, Fulgent Genetics' Non Operating Income stood at $7.8 million, which was up 63964.21% from -$1.8 million recorded in Q2 2025.
  • Fulgent Genetics' 5-year Non Operating Income high stood at $8.1 million for Q4 2024, and its period low was -$1.8 million during Q2 2025.
  • Its 3-year average for Non Operating Income is $5.4 million, with a median of $7.6 million in 2024.
  • Examining YoY changes over the last 5 years, Fulgent Genetics' Non Operating Income showed a top increase of 63964.21% in 2025 and a maximum decrease of 12347.89% in 2025.
  • Over the past 3 years, Fulgent Genetics' Non Operating Income (Quarter) stood at $5.9 million in 2023, then surged by 36.54% to $8.1 million in 2024, then fell by 3.08% to $7.8 million in 2025.
  • Its Non Operating Income stands at $7.8 million for Q3 2025, versus -$1.8 million for Q2 2025 and $8.1 million for Q1 2025.